In this Quick Case, Endocrinologist A/Prof Samantha Hocking outlines evidence from the SURMOUNT-MAINTAIN study, demonstrating how tirzepatide dose reduction or elimination impacts the maintenance of weight loss, cardiometabolic benefits, and clinical decision-making in obesity management (5 mins).
Lilly supports independent education on Healthed. Opt in to receive updates on relevant Lilly products, resources and events — directly, and only when there’s something worth sharing.
